title: Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma.
authors.affiliation: Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
authors.forename: H M
authors.initials: HM
authors.lastname: Dhingra
authors.forename: W K
authors.initials: WK
authors.lastname: Murphy
authors.forename: R J
authors.initials: RJ
authors.lastname: Winn
authors.forename: M N
authors.initials: MN
authors.lastname: Raber
authors.forename: W K
authors.initials: WK
authors.lastname: Hong
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000188:drug therapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; C013938:5,6-dihydro-5-azacytidine; D001374:Azacitidine